Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 24979 | 22.29 |
09:34 ET | 5121 | 22.31 |
09:36 ET | 9066 | 22.51 |
09:38 ET | 1500 | 22.44 |
09:39 ET | 1550 | 22.4344 |
09:41 ET | 2233 | 22.43 |
09:43 ET | 4214 | 22.4458 |
09:45 ET | 2750 | 22.43 |
09:48 ET | 5272 | 22.51 |
09:50 ET | 900 | 22.4 |
09:52 ET | 627 | 22.38 |
09:54 ET | 23271 | 22.46 |
09:56 ET | 1401 | 22.426 |
09:57 ET | 4000 | 22.46 |
09:59 ET | 8041 | 22.5463 |
10:01 ET | 12330 | 22.69 |
10:03 ET | 18061 | 22.625 |
10:06 ET | 6044 | 22.6725 |
10:08 ET | 5058 | 22.675 |
10:10 ET | 16503 | 22.65 |
10:12 ET | 4272 | 22.61 |
10:14 ET | 3010 | 22.51 |
10:15 ET | 15930 | 22.435 |
10:17 ET | 9501 | 22.44 |
10:19 ET | 3407 | 22.38 |
10:21 ET | 2829 | 22.37 |
10:24 ET | 6432 | 22.33 |
10:26 ET | 3668 | 22.275 |
10:28 ET | 6572 | 22.21 |
10:30 ET | 508 | 22.22 |
10:32 ET | 4490 | 22.18 |
10:33 ET | 8668 | 22.215 |
10:35 ET | 2482 | 22.25 |
10:37 ET | 8806 | 22.25 |
10:39 ET | 1244 | 22.23 |
10:42 ET | 4386 | 22.16 |
10:44 ET | 6367 | 22.1 |
10:46 ET | 4737 | 22.13 |
10:48 ET | 5903 | 22.17 |
10:50 ET | 3357 | 22.15 |
10:51 ET | 3750 | 22.15 |
10:53 ET | 382 | 22.1501 |
10:55 ET | 1826 | 22.17 |
10:57 ET | 7233 | 22.23 |
11:00 ET | 2168 | 22.156 |
11:02 ET | 3853 | 22.17 |
11:04 ET | 775 | 22.16 |
11:06 ET | 2307 | 22.175 |
11:08 ET | 919 | 22.1951 |
11:09 ET | 4008 | 22.23 |
11:11 ET | 4094 | 22.21 |
11:13 ET | 2407 | 22.22 |
11:15 ET | 2115 | 22.25 |
11:18 ET | 1887 | 22.29 |
11:20 ET | 1927 | 22.295 |
11:22 ET | 1100 | 22.28 |
11:24 ET | 4323 | 22.30564 |
11:26 ET | 2294 | 22.32 |
11:27 ET | 7998 | 22.32 |
11:29 ET | 14440 | 22.26 |
11:31 ET | 15453 | 22.29 |
11:33 ET | 16974 | 22.34 |
11:36 ET | 10724 | 22.34 |
11:38 ET | 6659 | 22.38 |
11:40 ET | 594 | 22.37 |
11:42 ET | 1455 | 22.39 |
11:44 ET | 13670 | 22.3888 |
11:45 ET | 3027 | 22.36 |
11:47 ET | 711 | 22.39 |
11:49 ET | 4008 | 22.44 |
11:51 ET | 1294 | 22.46 |
11:54 ET | 10636 | 22.48 |
11:56 ET | 7470 | 22.44 |
11:58 ET | 900 | 22.4699 |
12:00 ET | 100 | 22.44 |
12:02 ET | 3900 | 22.4488 |
12:03 ET | 10350 | 22.405 |
12:05 ET | 200 | 22.39 |
12:07 ET | 4700 | 22.3933 |
12:09 ET | 2022 | 22.4 |
12:12 ET | 1432 | 22.42 |
12:14 ET | 300 | 22.41 |
12:16 ET | 1228 | 22.44 |
12:18 ET | 15648 | 22.465 |
12:20 ET | 1300 | 22.5 |
12:21 ET | 2296 | 22.49 |
12:23 ET | 500 | 22.54 |
12:25 ET | 9376 | 22.52 |
12:27 ET | 1672 | 22.5019 |
12:30 ET | 2210 | 22.48 |
12:32 ET | 1800 | 22.44 |
12:34 ET | 800 | 22.42 |
12:36 ET | 4640 | 22.38 |
12:38 ET | 1898 | 22.35 |
12:39 ET | 1805 | 22.375 |
12:41 ET | 7008 | 22.37 |
12:43 ET | 300 | 22.36 |
12:45 ET | 1704 | 22.34 |
12:48 ET | 1198 | 22.34 |
12:50 ET | 1500 | 22.34 |
12:52 ET | 700 | 22.31 |
12:54 ET | 1117 | 22.28 |
12:56 ET | 1500 | 22.27 |
12:57 ET | 400 | 22.3 |
12:59 ET | 750 | 22.25 |
01:01 ET | 2100 | 22.24 |
01:03 ET | 8472 | 22.28 |
01:06 ET | 1568 | 22.2334 |
01:08 ET | 2200 | 22.29 |
01:10 ET | 1718 | 22.33 |
01:12 ET | 1900 | 22.27 |
01:14 ET | 1729 | 22.3 |
01:15 ET | 456 | 22.28 |
01:17 ET | 803 | 22.295 |
01:19 ET | 600 | 22.2911 |
01:21 ET | 3372 | 22.3165 |
01:24 ET | 3400 | 22.33 |
01:26 ET | 1458 | 22.33 |
01:28 ET | 2688 | 22.34 |
01:30 ET | 1180 | 22.27 |
01:32 ET | 1599 | 22.26 |
01:33 ET | 1063 | 22.28 |
01:35 ET | 100 | 22.3 |
01:37 ET | 600 | 22.28 |
01:39 ET | 1530 | 22.25 |
01:42 ET | 885 | 22.26 |
01:44 ET | 8151 | 22.28 |
01:46 ET | 300 | 22.311 |
01:48 ET | 1100 | 22.355 |
01:50 ET | 2687 | 22.34 |
01:51 ET | 5835 | 22.33 |
01:53 ET | 800 | 22.35 |
01:55 ET | 724 | 22.38 |
01:57 ET | 4972 | 22.3667 |
02:00 ET | 1097 | 22.35 |
02:02 ET | 238 | 22.36 |
02:04 ET | 1433 | 22.32 |
02:06 ET | 2400 | 22.33 |
02:08 ET | 1430 | 22.3232 |
02:09 ET | 100 | 22.34 |
02:11 ET | 1667 | 22.34 |
02:13 ET | 4800 | 22.2932 |
02:15 ET | 936 | 22.28 |
02:18 ET | 1105 | 22.285 |
02:20 ET | 800 | 22.27 |
02:22 ET | 1101 | 22.31 |
02:24 ET | 1382 | 22.27 |
02:26 ET | 1174 | 22.29 |
02:27 ET | 500 | 22.31 |
02:29 ET | 100 | 22.32 |
02:31 ET | 400 | 22.3 |
02:33 ET | 11105 | 22.26 |
02:36 ET | 906 | 22.27 |
02:38 ET | 2188 | 22.29 |
02:40 ET | 1300 | 22.28 |
02:42 ET | 600 | 22.278 |
02:44 ET | 1300 | 22.27 |
02:45 ET | 1039 | 22.29 |
02:47 ET | 2500 | 22.241 |
02:49 ET | 1071 | 22.22 |
02:51 ET | 1912 | 22.225 |
02:54 ET | 1070 | 22.26 |
02:56 ET | 1400 | 22.21 |
02:58 ET | 750 | 22.2 |
03:00 ET | 3972 | 22.1647 |
03:02 ET | 4991 | 22.175 |
03:03 ET | 2181 | 22.18 |
03:05 ET | 1450 | 22.22 |
03:07 ET | 3436 | 22.2596 |
03:09 ET | 500 | 22.22 |
03:12 ET | 5031 | 22.19 |
03:14 ET | 2886 | 22.2115 |
03:16 ET | 4397 | 22.22 |
03:18 ET | 874 | 22.23 |
03:20 ET | 1214 | 22.22 |
03:21 ET | 959 | 22.21 |
03:23 ET | 1633 | 22.198 |
03:25 ET | 1608 | 22.18 |
03:27 ET | 4793 | 22.18 |
03:30 ET | 3070 | 22.18 |
03:32 ET | 2887 | 22.1899 |
03:34 ET | 3257 | 22.2 |
03:36 ET | 6668 | 22.2 |
03:38 ET | 1034 | 22.22 |
03:39 ET | 5258 | 22.25 |
03:41 ET | 2206 | 22.23 |
03:43 ET | 4608 | 22.24 |
03:45 ET | 1786 | 22.23 |
03:48 ET | 8022 | 22.22 |
03:50 ET | 3264 | 22.245 |
03:52 ET | 8921 | 22.23 |
03:54 ET | 5956 | 22.2 |
03:56 ET | 11357 | 22.23 |
03:57 ET | 6231 | 22.185 |
03:59 ET | 272940 | 22.19 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 3.5B | 37.0x | --- |
Twist Bioscience Corp | 2.5B | -11.2x | --- |
Apellis Pharmaceuticals Inc | 3.5B | -10.2x | --- |
Zai Lab Ltd | 2.6B | -8.0x | --- |
Arrowhead Pharmaceuticals Inc | 2.4B | -4.1x | --- |
Alvotech SA | 3.7B | -4.6x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5B |
---|---|
Revenue (TTM) | $346.7M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $0.60 |
Book Value | $1.06 |
P/E Ratio | 37.0x |
Price/Sales (TTM) | 10.0 |
Price/Cash Flow (TTM) | 36.2x |
Operating Margin | 29.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.